Atossa Therapeutics (ATOS)
NASDAQ:ATOS
ATOS Stock Chart & Stats
$4.71
>-$0.01(-0.49%)
At close: 4:00 PM EST
$4.71
>-$0.01(-0.49%)
Day’s Range― - ―
52-Week Range$3.76 - $19.33
Previous CloseN/A
Volume314.80K
Average Volume (3M)1.16M
Market Cap
$40.56M
Enterprise Value-$739.17K
Total Cash (Recent Filing)$41.30M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.97
Next Earnings
May 18, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding8,611,428
10 Day Avg. Volume1,949,046
30 Day Avg. Volume1,157,820
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit46.20
Enterprise Value/Ebitda0.02
Forecast
1Y Price Target
$18.33Price Target Upside289.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Development PathwayAn oral formulation with an established favorable safety profile from prior oncology development supports a streamlined move into later-stage trials for Duchenne muscular dystrophy, which could accelerate clinical progress compared with novel therapeutic modalities.
Mechanism Of ActionPeer-reviewed data showing endoxifen may reduce inflammation, fibrosis and mitochondrial dysfunction through both estrogen receptor dependent and independent pathways supports a mutation-agnostic approach by upregulating utrophin, reinforcing the scientific rationale for treating Duchenne muscular dystrophy.
Regulatory IncentivesFDA designations for Duchenne muscular dystrophy, combined with Rare Pediatric Disease status and reauthorization of Priority Review Vouchers, could enable expedited review pathways and a transferable voucher that enhances the program's commercial and strategic value if approval is achieved.
Bears Say
Early-stage UncertaintyAnalyst assigns no value to the Duchenne program because it remains at a preclinical stage and competes in a crowded development landscape, indicating high scientific and regulatory risk before clinical proof of concept.
Financing RiskNotable share price decline and expectations of a need to raise capital create dilution risk and potential downward pressure on valuation, which could outweigh development advances absent clear financing plans.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $3.76 and its highest was $19.33 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $40.56M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is May 18, 2026 which is in 51 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Mar 25, 2026. The company reported -$1.19 earnings per share for the quarter, missing the consensus estimate of -$1.138 by -$0.052.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.92.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 8,611,428 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$1.19 in its last earnings report, missing expectations of -$1.138. Following the earnings report the stock price went down -13.1%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atossa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.33 (289.17% Upside)
$18.33 (289.17% Upside)
Hedge Fund Trend
Increased
By 3.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.34%
12-Months-Change
Fundamentals
Return on Equity
-49.42%
Trailing 12-Months
Asset Growth
-27.01%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$18.33
▲(289.17% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---